Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin in Treating Women With Hot Flashes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meeting 1 of the following criteria:~  * History of breast cancer (currently without malignant disease)~ * No history of breast cancer, but patient wishes to avoid estrogen due to a perceived increased risk of breast cancer~* Bothersome hot flashes (defined by their occurrence ≥ 28 times per week and of sufficient severity to make the patient desire therapeutic intervention)~* Presence of hot flashes for ≥ 1 month prior to study entry~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Life expectancy ≥ 6 months~* Able to complete questionnaire(s) by themselves or with assistance~* Women of childbearing potential not eligible (per the judgment of the attending clinician)~* Serum creatinine ≤ 1.5 times upper limit of normal~PRIOR CONCURRENT THERAPY:~* No prior gabapentin or pregabalin~* More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, or progestational agents~  * Vaginal estrogen is allowed if used for the past month and not planned to be discontinued~* Concurrent adjuvant targeted therapy (i.e., lapatinib, trastuzumab \[Herceptin®\]) allowed in patients with no evidence of disease~* Concurrent tamoxifen, raloxifene, or aromatase inhibitors on a constant dose for at least 4 weeks allowed provided the medication will not be stopped during the study period~* No concurrent or planned use of other agents for hot flashes except for any of the following:~  * Stable dose of vitamin E is allowed as long as agent was started \> 30 days prior to study initiation and is to be continued throughout the study period~ * Soy is allowed, if it is planned to be continued at the same dose during the study period~ * Stable dose of antidepressants is allowed as long as it was started \> 30 days prior to study initiation and is to be continued at a stable dose throughout the study period

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pregabalin75 (Type: EXPERIMENTAL): Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
- Pregabalin150 (Type: EXPERIMENTAL): Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo twice daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).